At BIOCAD, Dmitry Morozov leads a team of scientists rushing to make millions of doses from small amounts of the Russian COVID-19 vaccine. Dmitry says it’s a complex process, but the vaccine is already rolling off the production line at the company’s factory outside of St. Petersburg.
BIOCAD’s vital work during the pandemic is a world apart from Dmitry’s early life. He studied economics and business in Moscow and began working as a banker, but the job did not satisfy him. After taking an advanced business course in Japan, Dmitry returned to Russia inspired to start his own company. He founded BIOCAD in 2001 after realizing that “there was no biotech industry” in Russia.
Today, BIOCAD is one of the largest biotech companies in Russia. It develops and produces drugs to treat cancer and autoimmune diseases, as well as a treatment to alleviate complications from the coronavirus. The company has a portfolio of 60 registered products, some of which are supplied to the global market.
–
